John P. Leonard, MD

In this article, we review the methods of determining cell of origin (COO); use of COO in clinical practice; clinical trials in DLBCL according to COO; and future directions of tailoring treatment, including alternate categorization of genetic subtypes or clusters in DLBCL.

Given the benefit of rituximab to patients, it will be important that the use of biosimilar compounds not compromise the efficacy of treatment. However, measures to improve access to anti-CD20 therapy in a cost-effective manner will clearly provide benefit to patients with lymphoma.

Splenic lymphomas are a diverse group of lymphoid malignancies that have clinical behavior ranging from indolent to aggressive and that have both B-cell and T-cell histologies.

Mantle cell lymphoma (MCL) is a distinct subtype of non-Hodgkin lymphoma that occurs most commonly in older patients with advanced-stage disease.